's () chief executive Neil Clark talks to Proactive London's Polly Middlehurst about the company's focus on developing new anti-infectives for the prevention of infections.
Clark also discusses the government-funded COVID-19 product navel spray, part of a collaboration agreement with UK biotech SporeGen, to co-develop SporeGen's SPOR-COV product as a novel, preventive treatment.
Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Clark says they are "some great opportunities for quality assets that deliver solutions in this whole area of infection prevention".
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE